Jonas Busch1, Christoph Seidel2, Irena Goranova3, Barbara Erber3, Robert Peters3, Frank Friedersdorff3, Ahmed Magheli3, Kurt Miller3, Viktor Grünwald4, Steffen Weikert5. 1. Charité University Medicine Berlin, Department of Urology, Berlin, Germany. Electronic address: jonas.busch@charite.de. 2. University Medical Center Eppendorf, Department of Oncology/Hematology/Bone Marrow Transplantation/Pneumology, Hamburg, Germany. 3. Charité University Medicine Berlin, Department of Urology, Berlin, Germany. 4. Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany. 5. Charité University Medicine Berlin, Department of Urology, Berlin, Germany; Humboldt Vivantes Hospital Berlin, Department of Urology, Berlin, Germany.
Abstract
INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS. MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS . RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS. CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.
INTRODUCTION: Sequential use of targeted therapy (TT) has improved overall survival (OS) of patients with metastatic renal cell carcinoma (mRCC). The value of objective response (OR) as compared to stable disease (SD) is unclear. We aimed to investigate OR of first-line TT and its impact on OS. MATERIAL AND METHODS: Retrospective analysis of OS among 331 mRCC patients with a first-line assessment according to RECIST 1.0. Characteristics between objective responders (complete response [CR] or partial remission [PR]), patients with SD and non-responders (progressive disease [PD] and toxicity [Tox]) were compared with the Chi-square test and the Kruskal-Wallis test. Kaplan-Meier analysis of OS and progression-free survival (PFS). Cox model analysis of Predictors of OS . RESULTS: Best response was CR, PR, SD, PD and Tox in 9 (2.7%), 61 (18.4%), 167 (50.5%), 80 (24.2%) and 14 (4.2%) patients respectively resulting in an OR rate of 21%. Median OS in months: CR 63.2; PR 37.6; SD 35.9; PD 14.6; TOX 22.5 (p<0.0001). Median PFS for responders was 14.8, 11.5 for patients with SD and 2.5 for non-responders (p<0.0001). Similarly median OS was 38.7, 35.9 and 15.5 (p<0.00001). Primary resistance and a first-line PFS <6months were the strongest independent predictors of OS. The achievement of OR as compared to SD did not impact OS. CONCLUSIONS: In our cohort of unselected patients OR was not associated with superior OS as compared to SD.
Authors: Viktor Grünwald; Rana R McKay; Katherine M Krajewski; Daniel Kalanovic; Xun Lin; Julia J Perkins; Ronit Simantov; Toni K Choueiri Journal: Eur Urol Date: 2015-01-07 Impact factor: 20.096
Authors: Annika Fendler; Daniel Bauer; Jonas Busch; Klaus Jung; Annika Wulf-Goldenberg; Severine Kunz; Kun Song; Adam Myszczyszyn; Sefer Elezkurtaj; Bettina Erguen; Simone Jung; Wei Chen; Walter Birchmeier Journal: Nat Commun Date: 2020-02-17 Impact factor: 14.919